"Diphtheria Toxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADP-ribosylating polypeptide produced by CORYNEBACTERIUM DIPHTHERIAE that causes the signs and symptoms of DIPHTHERIA. It can be broken into two unequal domains: the smaller, catalytic A domain is the lethal moiety and contains MONO(ADP-RIBOSE) TRANSFERASES which transfers ADP RIBOSE to PEPTIDE ELONGATION FACTOR 2 thereby inhibiting protein synthesis; and the larger B domain that is needed for entry into cells.
| Descriptor ID |
D004167
|
| MeSH Number(s) |
D08.811.913.400.725.115.220 D23.946.123.305
|
| Concept/Terms |
Diphtheria Toxin- Diphtheria Toxin
- Toxin, Corynebacterium Diphtheriae
- Corynebacterium Diphtheriae Toxin
|
Below are MeSH descriptors whose meaning is more general than "Diphtheria Toxin".
Below are MeSH descriptors whose meaning is more specific than "Diphtheria Toxin".
This graph shows the total number of publications written about "Diphtheria Toxin" by people in this website by year, and whether "Diphtheria Toxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diphtheria Toxin" by people in Profiles.
-
Ablation of Pericyte-Like Cells in Lungs by Oropharyngeal Aspiration of Diphtheria Toxin. Am J Respir Cell Mol Biol. 2017 Feb; 56(2):160-167.
-
Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Anticancer Drugs. 2008 Nov; 19(10):1007-11.
-
Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma. 2007 Apr; 48(4):808-11.
-
Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. Cancer Immunol Immunother. 2006 Aug; 55(8):928-32.
-
Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res. 2005 Jan 01; 11(1):329-34.
-
Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug; 54(8):799-806.
-
Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk Lymphoma. 2004 Aug; 45(8):1647-56.
-
Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif. 2004 Jan; 33(1):123-33.
-
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3555-61.
-
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002 May; 8(5):1004-13.